AACR Round-Up: BMS, Lilly, iTeos, Affimed, Treovir, Revolution And Cardiff
Immuno-Oncology Highlights Include TIGIT, NK Cell Booster & HSV Oncolytic
iTeos presents early anti-TIGIT results, Affimed reports 100% response rate in Hodgkin lymphoma, Treovir will start a pivotal Phase II after Phase I pediatric glioma study, updates in KRAS-mutated cancers from Revolution Medicines and Cardiff Oncology, plus Opdivo plus chemo shows complete responses in neoadjuvant lung cancer and Lilly’s Retevmo is active in additional tumors.
